Doctor Scott M. Rocklage joined 5AM ventures in the year 2003. He commenced his career in this organization as a venture partner. Based on his outstanding performance, he became a managing partner in 5AM Ventures in 2004.
The strategic leadership portrayed by Dr. Scott is attributed to his educational background and experience in healthcare fields. He has over twenty years’ expertise in superintendence in the healthcare field. Read more: Scott Racklage | Crunchbase and Scott Racklage | Bloomberg
The input of Dr. Scott is depicted by the strategic leadership responsibility portrayed by his successful effort towards approval of the US New Drug Applications. Under the leadership of Dr. Scott, three US New Drugs application were approved by the FDA. His contribution in shaping the healthcare system entailed entering six candidates in clinical trials.
Dr. Scott has worked in various organizations hence gathering extensive expertise that enables him to successfully play his tasks within 5AM Ventures. Scott has subserved as a CEO and chairman of Cubist Pharmaceuticals.
In addition to this, he has worked as chairman and CEO to Nycomed Interventional. His work period at Catalytica and Salutar also adds up to the experience he possesses since he held different R&D positions within these two organizations.
Currently, Dr. Scott holds various leadership positions in several organizations. This depicts the trust that the companies have for him hence under his leadership, improved performance is expected.
He serves as a Board Chairman in Semprus, Relypsa, and Achaogen. Dr. Scott obtained a BS in Chemistry from California University. He also earned a Ph.D. in the same field from Massachusetts Institute of Technology. The headquarter offices of Dr. Scott are situated at Waltham.
The difference between Dr. Scott Rocklage and other entrepreneurs is that his business is science based. As such, the company he leads aims to make scientific innovations designed to improve the lives of people. The company is named 5AM Ventures since it is considered to be at an early age of development.
As such, more progress is expected. The ideas implemented by Dr. Scott are brought to life through discussions with business executives, physicians, and scientists. Such ideas aim at treating the unmet medical needs.